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Eleftherios P Diamandis1,2,3,4Abstract
Background: Most of newly discovered cancer biomarkers fail in the clinic because they lack sensitivity and/or
specificity. The current explosion in knowledge of the mutational spectrum of many cancer types, as a result of
whole exome and whole genome sequencing, has revealed a wide spectrum of mutations that appear to be highly
specific for various cancer types.
Discussion: Mass spectrometry (MS) has the ability to monitor tryptic peptides in complex biological mixtures with
high sensitivity and specificity. It may be possible in the near future to combine the known spectrum of gene
mutations revealed by genomics with the power of MS, in order to quantify mutant peptides that are highly
specific for cancer, in a multiplex fashion. Such mutant peptides, quantified in the circulation and other fluids, may
represent tumor markers that are suitable for detection and monitoring of cancer.
Summary: The power of genomic and proteomic technologies can be combined to identify highly specific
analytes for biomarker applications.
Keywords: Cancer biomarker, Genomics, Proteomics, Mutant proteins, High specificity, Selected reaction
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The National Institutes of Health define biomarkers as cel-
lular, biochemical, and/or molecular (including genetic
and epigenetic) characteristics by which normal and/or
abnormal processes can be recognized and/or monitored.
Biomarkers are measurable in biological materials, such as
in tissues, cells, and/or bodily fluids. There are many ex-
amples of powerful biomarkers that are currently being
used in clinical practice (for example, troponin, glucose,
creatinine, and thyroid stimulating hormone, to mention
only a few). Unfortunately, the current situation with can-
cer biomarkers is not so bright. Despite the fact that a
handful of biomarkers are currently used in the clinic,
none of them is useful for the highest-impact applications
of population screening and early diagnosis. Currently,
cancer biomarkers are deployed to aid in assessing thera-
peutic response in patients with advanced cancer or toCorrespondence: ediamandis@mtsinai.on.ca
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unless otherwise stated.provide earlier detection of relapse in patients who have
been treated [1]. The main reason for their restricted use
is that current cancer biomarkers are not cancer-specific
proteins that are implicated in cancer initiation or pro-
gression, but rather molecules that are found in both nor-
mal and cancerous tissues, sometimes in roughly the same
amounts. As would be expected, none of these markers is
highly specific for cancer, and they are usually elevated in
both malignant and non-malignant processes of the or-
gans/cells that produce them.
Recently, it has been postulated that the emergence of
highly powerful “omics” technologies, such as genomics,
epigenomics, transcriptomics, proteomics, and metabo-
lomics, may revolutionize the discovery of novel cancer
biomarkers and/or panels, with distinct advantages over
the currently used biomarkers [2]. However, this promise
has not yet been fulfilled. Some of the reasons for the
difficulties in discovering novel and improved cancer
biomarkers have been discussed elsewhere [3,4]. In
short, most of the newly discovered biomarkers either
represent false discoveries, or are characterized by speci-
ficity that is similar, or more frequently, inferior to that
of the currently used cancer biomarkers.d. This is an Open Access article distributed under the terms of the Creative
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Cancer heterogeneity
More recently, it has been recognized that cancer is a
highly heterogeneous disease [5,6]. For example, several
forms of epithelial ovarian cancer are currently recog-
nized: high-grade serous (approximately 65% of cases),
endometrioid (approximately 15%), clear cell (approxi-
mately 10%), low-grade serous (approximately 5%), and
mucinous (approximately 5%) carcinoma. The muta-
tional landscapes of these types of epithelial ovarian
cancers are very different, with the serous histotype
characterized by very high frequency of TP53 mutations
(96%) [7], and other subtypes having TP53 mutations
much less frequently (>30%) but having more frequent
mutations in other genes (data from the Broad Insti-
tute’s tumor portal [8]). It is thus not surprising, given
this information, that finding one universal cancer bio-
marker for all subtypes of epithelial ovarian cancer will
be highly unlikely.
Cancer-specific biomarkers
Do molecules that can only be found in cancer cells
exist, and can they be identified? Such molecules could
be highly specific markers for cancer and, if sufficiently
sensitive, could represent the new generation of clinic-
ally useful biomarkers. Although some such cancer bio-
markers have been identified (for example, translocation
of parts of chromosomes 9 and 22 in chronic myeloge-
nous leukemia, which creates an oncogenic BCR-ABL
gene fusion; and some other translocations in rare can-
cers) these are the exceptions. For the most common
forms of cancer, we do not as yet have cancer-specific
molecules that can be used as biomarkers. Recently, I
proposed that it may be possible in the future to identify
“rare” tumor markers that occur in a small percentage
(possibly 2 to 5%) of patients but have extremely high
specificity (close to 100%) [9]. Here, I postulate that the
new advances in genomics provide the opportunity to
identify true cancer biomarkers. This may represent a
possible solution to the stagnation of the cancer bio-
marker field over the past 30 years [10].
Genomic alterations in cancer
Recently, Lawrence et al. analyzed the mutational spectrum
of 21 cancer types within 4,742 specimens for which the
exomes had been sequenced. This vast amount of new gen-
omic data revealed that the number of significantly mu-
tated genes (those present in >2% of tumors) in the 21
cancer types varied tremendously, from 1 to 58, with a
mean of approximately 20. The Cancer Genome Atlas Re-
search Network published the exomic sequencing of 316
serous ovarian cancers, and identified over 300 mutations,
mostly affecting the TP53 gene [7]. An important point
made by Lawrence et al. is that the mutations so faridentified represent an incomplete list. They calculated that
in order to catalogue nearly all mutations found in human
cancers, it will be necessary to sequence 600 to 5,000 tu-
mors for each cancer type.
How could we translate this information into clinically
useful biomarkers? Kandoth et al. showed that around 127
genes were significantly mutated in a combined analysis of
3,281 tumors, representing 12 tumor types [11,12]. Of
these genes, a few (such as BAP1, DNMT3A, KDM5C,
FBX7 and TP53) were associated with poor prognosis,
whereas mutations in two genes (BRCA2 and IDH1) cor-
related with favorable prognosis. Thus, some mutated
genes are progrnostic markers. Kinde et al., in an effort to
translate some of the genomic findings into clinical diag-
nostic tools, collected Pap smears from patients with
endometrial and ovarian cancers, and analyzed DNA from
these samples to find mutations that are known to be as-
sociated with these cancers [13]. They could identify at
least one mutation in all 24 endometrial cancers and in
40% (9 of 22) of ovarian cancers. Mutational analysis was
performed with a highly sensitive and specific assay (Safe-
Sequencing System; Safe-Seq S) which is immune to the
presence of a vast excess of normal alleles [14]. An import-
ant finding of this study is that the specificity of the test
was 100% in both cases, although the sample size was
small (n = 14).
Proteogenomics
Taking this one step further, it is reasonable to speculate
that the encoded mutated proteins may represent the
long-sought, highly specific cancer biomarkers of the fu-
ture. To exemplify this point in some detail, I will use
one example of the mutational spectrum reported by
Kinde et al. for ovarian cancer [13]. The same concept
can be applied to the myriad recently revealed mutations
in other genes or other cancer types [11].
One mutation in the TP53 gene reported by Kinde et
al. is the V147D missense mutation, found in one out of
the twenty-two ovarian cancers. Examination of tryptic
peptides from p53 revealed that the normal allele will
produce the tryptic peptide TCPVQLWVDSTPPPGTR,
while the mutant allele will produce the peptide
TCPVQLWDDSTPPPGTR (bold type indicates amino
acid change). Examination of SRM Atlas [15] and GPM
Global Proteome Machine [16] revealed that this pep-
tide is present in both databases, and has a predicted
m/z ratio of 955.9 as a doubly positively charged ion.
Thus, development of a sensitive selected reaction mon-
itoring (SRM) assay for both the wild-type and mutant
peptides should be feasible.
Why would a proteomic/mass spectrometry (MS) method
be advantageous over genomic approaches for identifying
these mutations? First, it may be possible to identify mu-
tated proteins that are secreted or membrane-bound, with
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thus be accessible for analysis in blood. This may not be
the case with genomic analysis, which requires tumor-
specific DNA in the circulation. Second, at least theore-
tically, the mutated peptide should represent a unique
fragment not present in normal cells (that is, a “true”
cancer-specific biomarker). Third, the expected different
fragmentation patterns of the wild-type and mutant pep-
tides (due to a different amino acid in the mutated pos-
ition) suggests that SRM analysis of the mutant peptide
should be free from any interference by the wild-type pep-
tide, even if the latter is present in huge excess. This
speculation needs experimental verification.
As mentioned previously [9], it may be possible to
utilize rare tumor markers (such as the ones mentioned
above) for diagnosis and monitoring of those patients
who are informative for this biomarker, despite low sen-
sitivity (but excellent specificity). The vast number of
mutations that have been revealed for ovarian and other
cancers provide opportunities for combining rare, but
highly specific, mutant peptides into a panel to improve
sensitivity, while retaining outstanding specificity. The
SRM assay is amenable to multiplexing, and more than
500 peptides can be monitored simultaneously with mul-
tiple transitions [17,18]. Thus, monitoring in parallel
many peptides in one sample is highly realistic.
Shortcomings
What are the possible shortcomings of such a method and
ways around them? At the technical level, additional ad-
vances in MS will allow even greater multiplexing capabil-
ity and higher sensitivity in detecting peptide fragments in
SRM assays, in the presence of vast amounts of other pep-
tides. It is also possible that some recently developed sam-
ple preparation protocols, such as stable isotope standard
capture with anti-peptide antibodies (SISCAPA) [19] and
others [20-22] may further help in enriching for the moni-
tored peptides. It should also be expected that not all gen-
etic mutations will be associated with tryptic peptides that
have high ionization efficiency and can thus be detected
by SRM. Moreover, the m/z ratio of these peptides may
fall outside the dynamic range of current instruments. An-
other important caveat would be the abundance of the
mutant peptide in the sample of interest, in comparison
with the total amount of peptides in the tryptic mixture.
Ion suppression may not allow efficient ionization of the
peptide of interest. The detection of a few copies of a mu-
tant peptide in a highly complex mixture such as a serum
digest is likely to be a daunting task [23]. Underexpressed
proteins will be even more difficult to quantify.
At the biological level, it may well be that many of
these mutations are rare, or exist in proteins that are nu-
clear or cytoplasmic and thus not present in the circula-
tion. In such cases, an easily accessible biological fluidmay be a good substitute. Examples would be Pap
smears and cervicovaginal fluid for endometrial, cervical,
and ovarian cancer; sputum and bronchoalveolar lavage
for oral and lung cancer, urine for bladder and prostate
cancer; seminal plasma for prostate and testicular can-
cer; nipple aspirate fluid for breast cancer; and pancre-
atic juice for pancreatic cancer. Last, but not least, it
should be emphasized that the identified mutations in
cancer may not be oncogenic or even specific for cancer.
Thus, the specificity of this approach needs to be experi-
mentally determined.Summary
The majority of new biomarkers fail because they lack the
necessary sensitivity and specificity to address an unmet
clinical need. Our current ability to sequence tumor ge-
nomes provided a wide spectrum of mutations in many
cancer types, which appear to be highly specific for cancer.
Current advances in mass spectrometry allow for highly
sensitive and specific monitoring of proteotypic peptides
in complex biological mixtures. I speculate here that by
combining the known mutational spectrum of genes, with
the ability of MS to quantify mutant peptides in the pres-
ence of vast amounts of normal peptides in a multiplex
fashion, we may be able to develop cancer-specific assays.
It remains to be seen if this combination can lead to can-
cer biomarkers that have better characteristics than the
ones currently used in the clinic.
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